Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 595

1.

Can the Antisecretory Factor Be Considered a New Therapy for the Short Bowel Syndrome?

Viggiani MT, Di Leo A, Barone M.

Nutr Metab Insights. 2019 May 23;12:1178638819852061. doi: 10.1177/1178638819852061. eCollection 2019.

PMID:
31205420
2.

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C, Arpino G, Bernardo A, Martignetti A, Risi E, Pestrin M, Boni L, Benelli M, Biganzoli L, Di Leo A, Malorni L.

Breast Cancer Res. 2019 May 29;21(1):71. doi: 10.1186/s13058-019-1149-5.

3.

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.

Robertson JFR, Jiang Z, Di Leo A, Ohno S, Pritchard KI, Ellis M, Bradbury I, Campbell C.

Breast Cancer. 2019 May 11. doi: 10.1007/s12282-019-00973-4. [Epub ahead of print]

PMID:
31079343
4.

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart M, Gradishar WJ, Chia S, Di Leo A, Malorni L.

Eur J Cancer. 2019 Jun;114:55-66. doi: 10.1016/j.ejca.2019.04.002. Epub 2019 May 3.

PMID:
31059974
5.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J; SOLE Investigators.

Br J Cancer. 2019 May;120(10):959-967. doi: 10.1038/s41416-019-0435-4. Epub 2019 Apr 10.

PMID:
30967649
6.

Increased cancer risk in patients undergoing dialysis: a population-based cohort study in North-Eastern Italy.

Taborelli M, Toffolutti F, Del Zotto S, Clagnan E, Furian L, Piselli P, Citterio F, Zanier L, Boscutti G, Serraino D; Italian Transplant & Cancer Cohort Study.

BMC Nephrol. 2019 Mar 28;20(1):107. doi: 10.1186/s12882-019-1283-4.

7.

The Spectrum of Small Intestinal Lesions in Patients with Unexplained Iron Deficiency Anemia Detected by Video Capsule Endoscopy.

Contaldo A, Losurdo G, Albano F, Iannone A, Barone M, Ierardi E, Di Leo A, Principi M.

Medicina (Kaunas). 2019 Feb 27;55(3). pii: E59. doi: 10.3390/medicina55030059.

8.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group.

Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.

PMID:
30765258
9.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Lancet. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8.

10.

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.

Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R.

Pharmacogenomics J. 2019 Feb 6. doi: 10.1038/s41397-019-0077-1. [Epub ahead of print]

11.

The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review.

Rossi L, McCartney A, De Santo I, Risi E, Moretti E, Malorni L, Biganzoli L, Di Leo A.

Cancer Treat Rev. 2019 Mar;74:29-34. doi: 10.1016/j.ctrv.2019.01.007. Epub 2019 Jan 25. Review.

PMID:
30708267
12.

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP.

NPJ Breast Cancer. 2019 Jan 17;5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019.

13.

Lessons learned from 227 biological meshes used for the surgical treatment of ventral abdominal defects.

Baldan N, Munegato G, Di Leo A, Lauro E, Morpurgo E, Pianigiani S, Briscolini D, Ferrara R, Fiscon V, Brolese A, De Manzoni G, Baldazzi G, Snidero D, Merigliano S, Ricci F, Laterza E, Merenda R, Gianesini R; NEI-Meshing Collaborative.

Hernia. 2019 Jan 19. doi: 10.1007/s10029-019-01883-2. [Epub ahead of print]

PMID:
30661179
14.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 .

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy537. [Epub ahead of print] No abstract available.

PMID:
30624592
15.

Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.

Dellapasqua S, Gray KP, Munzone E, Rubino D, Gianni L, Johansson H, Viale G, Ribi K, Bernhard J, Kammler R, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Colleoni M; International Breast Cancer Study Group.

J Clin Oncol. 2019 Feb 10;37(5):386-395. doi: 10.1200/JCO.18.00296. Epub 2018 Dec 27.

PMID:
30589600
16.

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.

Di Leo A, O'Shaughnessy J, Sledge GW Jr, Martin M, Lin Y, Frenzel M, Hardebeck MC, Smith IC, Llombart-Cussac A, Goetz MP, Johnston S.

NPJ Breast Cancer. 2018 Dec 18;4:41. doi: 10.1038/s41523-018-0094-2. eCollection 2018.

17.

ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data.

Romagnoli D, Boccalini G, Bonechi M, Biagioni C, Fassan P, Bertorelli R, De Sanctis V, Di Leo A, Migliaccio I, Malorni L, Benelli M.

BMC Genomics. 2018 Dec 24;19(1):960. doi: 10.1186/s12864-018-5249-x.

18.

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Rossi L, McCartney A, Risi E, Malorni L, Biganzoli L, Di Leo A.

Ther Adv Med Oncol. 2018 Dec 10;10:1758835918815591. doi: 10.1177/1758835918815591. eCollection 2018.

19.

Predictivity of Autoimmune Stigmata for Gluten Sensitivity in Subjects with Microscopic Enteritis: A Retrospective Study.

Losurdo G, Principi M, Iannone A, Giangaspero A, Piscitelli D, Ierardi E, Di Leo A, Barone M.

Nutrients. 2018 Dec 18;10(12). pii: E2001. doi: 10.3390/nu10122001.

20.

Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors.

Barone M, Viggiani MT, Anelli MG, Fanizzi R, Lorusso O, Lopalco G, Cantarini L, Di Leo A, Lapadula G, Iannone F.

J Clin Med. 2018 Dec 1;7(12). pii: E504. doi: 10.3390/jcm7120504.

21.

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer.

Guarducci C, Bonechi M, Benelli M, Biagioni C, Boccalini G, Romagnoli D, Verardo R, Schiff R, Osborne CK, De Angelis C, Di Leo A, Malorni L, Migliaccio I.

NPJ Breast Cancer. 2018 Nov 28;4:38. doi: 10.1038/s41523-018-0092-4. eCollection 2018.

22.

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group.

J Clin Oncol. 2019 Jan 10;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26.

PMID:
30475668
23.

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.

Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M; collaborators.

Dig Liver Dis. 2019 Feb;51(2):310-317. doi: 10.1016/j.dld.2018.10.014. Epub 2018 Oct 31.

PMID:
30473220
24.

Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.

Belluco C, Forlin M, Delrio P, Rega D, Degiuli M, Sofia S, Olivieri M, Pucciarelli S, Zuin M, De Manzoni G, Di Leo A, Scabini S, Zorcolo L, Restivo A.

BMC Cancer. 2018 Nov 12;18(1):1094. doi: 10.1186/s12885-018-5022-1.

25.

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data.

Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at www.progettopiter.it.

Pharmacoeconomics. 2019 Feb;37(2):255-266. doi: 10.1007/s40273-018-0733-3.

PMID:
30378086
26.

Clinical relevance of serum non-organ-specific antibodies in patients with HCV infection receiving direct-acting antiviral therapy.

Shahini E, Iannone A, Romagno D, Armandi A, Carparelli S, Principi M, Viggiani MT, Ierardi E, Di Leo A, Barone M.

Aliment Pharmacol Ther. 2018 Nov;48(10):1138-1145. doi: 10.1111/apt.14999.

PMID:
30375693
27.

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?

McCartney A, Di Leo A, Malorni L.

Oncotarget. 2018 Sep 25;9(75):34031-34032. doi: 10.18632/oncotarget.26133. eCollection 2018 Sep 25. No abstract available.

28.

Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials.

Iannone A, Ruospo M, Wong G, Barone M, Principi M, Di Leo A, Strippoli GFM.

Can J Gastroenterol Hepatol. 2018 Sep 16;2018:5437135. doi: 10.1155/2018/5437135. eCollection 2018.

29.

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.

Pelizzari G, Arpino G, Biganzoli L, Cinieri S, De Laurentiis M, Del Mastro L, Di Leo A, Gori S, Guarneri V, Marchetti P, Puglisi F.

BMC Cancer. 2018 Sep 27;18(1):932. doi: 10.1186/s12885-018-4843-2.

30.

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A; International Breast Cancer Study Group Trial 23-01.

Lancet Oncol. 2018 Oct;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2. Epub 2018 Sep 5.

PMID:
30196031
31.

In Reply to Belkacemi and Tsoutsou.

Zeidan YH, Habib JG, de Azambuja E, Campbell I, Andersson M, Lluch A, Di Leo A, Francis PA.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):467-468. doi: 10.1016/j.ijrobp.2018.06.010. No abstract available.

PMID:
30191880
32.

Proximate, fatty acids and metals in edible marine bivalves from Italian market: Beneficial and risk for consumers health.

Prato E, Biandolino F, Parlapiano I, Giandomenico S, Denti G, Calò M, Spada L, Di Leo A.

Sci Total Environ. 2019 Jan 15;648:153-163. doi: 10.1016/j.scitotenv.2018.07.382. Epub 2018 Jul 31.

PMID:
30114586
33.

Survival after the diagnosis of de novo malignancy in liver transplant recipients.

Taborelli M, Piselli P, Ettorre GM, Baccarani U, Burra P, Lauro A, Galatioto L, Rendina M, Shalaby S, Petrara R, Nudo F, Toti L, Fantola G, Cimaglia C, Agresta A, Vennarecci G, Pinna AD, Gruttadauria S, Risaliti A, Di Leo A, Rossi M, Tisone G, Zamboni F, Serraino D; Italian Transplant and Cancer Cohort Study.

Int J Cancer. 2019 Jan 15;144(2):232-239. doi: 10.1002/ijc.31782. Epub 2018 Oct 26.

PMID:
30091809
34.

Chemoprevention of inflammation-related colorectal cancer by silymarin-, acetyl-11-keto-beta-boswellic acid-, curcumin- and maltodextrin-enriched dietetic formulation in animal model.

Girardi B, Principi M, Pricci M, Giorgio F, Iannone A, Losurdo G, Ierardi E, Di Leo A, Barone M.

Carcinogenesis. 2018 Oct 8;39(10):1274-1282. doi: 10.1093/carcin/bgy104.

PMID:
30084990
35.

Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.

Rossi L, Biagioni C, McCartney A, Moretti E, Pestrin M, Sanna G, Risi E, Malorni L, DI Leo A, Biganzoli L.

Anticancer Res. 2018 Aug;38(8):4839-4845. doi: 10.21873/anticanres.12795.

PMID:
30061257
36.

New fecal test for non-invasive Helicobacter pylori detection: A diagnostic accuracy study.

Iannone A, Giorgio F, Russo F, Riezzo G, Girardi B, Pricci M, Palmer SC, Barone M, Principi M, Strippoli GF, Di Leo A, Ierardi E.

World J Gastroenterol. 2018 Jul 21;24(27):3021-3029. doi: 10.3748/wjg.v24.i27.3021.

37.

A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal.

Lovero R, Losurdo G, Mastromauro M, Castellaneta NM, Mongelli A, Gentile A, Di Leo A, Principi M.

Curr Drug Saf. 2018;13(3):221-223. doi: 10.2174/1574886313666180719165212.

PMID:
30027852
38.

Biological markers for non-celiac gluten sensitivity: a question awaiting for a convincing answer.

Ierardi E, Losurdo G, Piscitelli D, Giorgio F, Amoruso A, Iannone A, Principi M, Di Leo A.

Gastroenterol Hepatol Bed Bench. 2018 Summer;11(3):203-208. Review.

39.

Differences in dietary habits between patients with inflammatory bowel disease in clinical remission and a healthy population.

Principi M, Losurdo G, Iannone A, Contaldo A, Deflorio V, Ranaldo N, Pisani A, Ierardi E, Di Leo A, Barone M.

Ann Gastroenterol. 2018 Jul-Aug;31(4):469-473. doi: 10.20524/aog.2018.0273. Epub 2018 May 7.

40.

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.

De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.

BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23.

PMID:
29956884
41.

Novel steps forward in the histopathology of non-celiac gluten sensitivity.

Losurdo G, Piscitelli D, Di Leo A.

Virchows Arch. 2018 Oct;473(4):523. doi: 10.1007/s00428-018-2388-z. Epub 2018 Jun 18. No abstract available.

PMID:
29915943
42.

The role of abemaciclib in treatment of advanced breast cancer.

McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, Biganzoli L, Di Leo A.

Ther Adv Med Oncol. 2018 May 31;10:1758835918776925. doi: 10.1177/1758835918776925. eCollection 2018. Review.

43.

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.

Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A.

Ann Oncol. 2018 Aug 1;29(8):1748-1754. doi: 10.1093/annonc/mdy214.

PMID:
29893790
44.

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group.

N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4.

45.

Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept.

Rendina M, Castellaneta NM, Losurdo G, Castellaneta A, Cazzolla A, Chialà C, D'Errico F, Di Leo A.

Ther Adv Chronic Dis. 2018 Jun;9(6):121-123. doi: 10.1177/2040622318755651. Epub 2018 Feb 12. No abstract available.

46.

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group.

Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28.

PMID:
29808463
47.

Metabolomics in breast cancer: A decade in review.

McCartney A, Vignoli A, Biganzoli L, Love R, Tenori L, Luchinat C, Di Leo A.

Cancer Treat Rev. 2018 Jun;67:88-96. doi: 10.1016/j.ctrv.2018.04.012. Epub 2018 May 3. Review.

PMID:
29775779
48.

Estrogen receptor β controls proliferation of enteric glia and differentiation of neurons in the myenteric plexus after damage.

D'Errico F, Goverse G, Dai Y, Wu W, Stakenborg M, Labeeuw E, De Simone V, Verstockt B, Gomez-Pinilla PJ, Warner M, Di Leo A, Matteoli G, Gustafsson JA.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):5798-5803. doi: 10.1073/pnas.1720267115. Epub 2018 May 14.

49.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Oct 1;29(10):2153. doi: 10.1093/annonc/mdx806. No abstract available.

PMID:
29733336
50.

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.

Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A, Di Marco V, Lampertico P, Brunetto MR, Zuin M, Andreone P, Villa E, Troshina G, Calvaruso V, Degasperi E, Coco B, Giorgini A, Conti F, Di Leo A, Marzi L, Boccaccio V, Bollani S, Maisonneuve P, Bruno S.

Aliment Pharmacol Ther. 2018 Jun;47(12):1705-1712. doi: 10.1111/apt.14685. Epub 2018 May 3.

PMID:
29722439

Supplemental Content

Loading ...
Support Center